Training My Thoughts

Rode the train up to DC from Charlottesville on Friday night and, let me tell you, despite all the years and money thrown at...

October Awaits

September to remember? I had such high hopes. Sadly, it turned out to be a very forgettable month and I'm happy to have it...

When The Tide Goes Out, You See Who’s Swimming Naked…

The markets had another downward-trending week since the last newsletter. However, the overall tone of the market felt better from a micro-cap investing standpoint...

Rolling Over? Markets Look Toppy To Me…

As I wrote about last week, we are entering what is historically the worst stretch of time for the market. I'm not sure why...

A September To Remember?

I read this week where someone said, "the short story is always sexier." There's certainly a lot of truth in that. Here in September...

Alzheimer’s Patients Treated with INmune Bio’s XPro™ Show Reduction in CSF Phospho-Tau and Evidence...

TW's Take: outstanding that demonstrates XPro195 is very effective in clearing neuroinflammation and reducing biomarkers associated with declining cognition. Very important PR that positions...

Small Caps Rebound…August Recap

I'm calling it a month. Normally, I'd wait until August is officially over before recapping things, but, since we only have two days of...

INKmune Induces Memory-Like NK Cells…This Is A Very Big Deal

In July, INmune Bio (INMB) dosed their first cancer patient with INKmune. Last night, we got an update on the program. Admittedly, there's only...

Old Fashioned Sunday

While the bankers and fund managers are heading out to the Hamptons for vacation, micro-cap earnings season kicked in last week and news flow...

INKmune: An Interview With INmune Bio’s Dr. Mark Lowdell

TW Research (TW): Dr. Lowdell, thanks for speaking with us today. I know you’ve been involved with INKmune since the very beginning and was...

Summer Stocks

The markets seem to be quieting down as summer heats up and traders are heading to the beach for the last few weeks of...

My Saturday Rant…

If you've been reading this newsletter for longer than two weeks, you likely have come to realize that I'm an investor not a trader....

INmune Bio, Inc. Announces Second Quarter 2021 Results and Provides Business Update

TW's Take: while we await the Alzheimer's data later in August, the INKmune program seems to be showing excellent activity at two weeks. Quellor...

Are We Having Fun Yet? Bull Ride Continues

The "bull" market continued this past week although it showed signs of tiring. Which is good because the bull ride we've been on resembles...

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and...

TW's Take: Very exciting news. The data is compelling and improves over time. Meanwhile, having a rigorous, placebo controlled trial that only lasts 6...

July About to Close With a Bang?

Last week wasn't a bad week for the markets at all. With a nice two day rally to end the week, the Russell 2000...

INmune Bio, Inc. Announces Poster Presentation and Plenary Talk at the Alzheimer’s Association International...

TW's Take: INmune's data on reducing neuro-inflammation is industry leading. Their lack of cognitive testing has led to a discounted valuation versus peers that...

Back In The Torture Chamber

With the S&P 500 hitting new highs recently, continuing the rally from last March's lows, we are all having a great time, right? Uhhh,...

INmune Bio, Inc. Announces $40 Million Registered Direct Offering

TW's Take: a smart move putting quality investors into the stock and getting enough cash to take them through phase 2. Painful to stop...

INmune Bio, Inc. Announces First Patient Treated with NK cell priming “pseudokine” INKmune in...

TW's Take: great news as this program had been long-delayed by Covid. NK companies routinely achieve valuations higher than INMB's current market cap. This...

Kentucky Bluegrass

In a holiday shortened week, this newsletter comes from Kentucky where the TW household is attending a family wedding. Throw in a side journey...

Let’s Get Ready To Rumble (2nd Half Preview)

To steal a line from Charles Dickens, "It was the best of times. It was the worst of times. Then it was pretty darn...

Hoping for Fireworks

As the market seems to be slowly settling into summer, volatility is dropping and news flow is getting sparse. Amazing to think this is...

Put The Hammer Down…Backgammon Lessons

Back in February, on our trip to Miami, I was fortunate to be introduced to a friend of a friend named "Phil". Phil just...

Warrant Repo Is A Coup For INmune

Yesterday afternoon, INmune Bio (INMB) announced that they had taken out a loan from Silicon Valley Bank with the use of proceeds a repurchase...

INmune Bio, Inc. Announces $15 Million Credit Facility to Purchase Xencor Option to Reduce...

TW's Take: very positive expression of confidence on the part of management and a wonderful deal for shareholders. Very happy to be rid of...

Stock Picking Wins This Week

It was another great week for TW as the pendulum appears to be swinging full speed in our direction. This while the overall market...

Aducanumab Approval…Implications For INmune Bio

Yesterday the FDA gave a highly controversial approval to Biogen (BIIB) for the first ever treatment of Alzheimer's. In doing so, the FDA has...

Oregon Trails

Greetings from Ashland, Oregon where my tour of the west coast is ending in fine fashion. The biking here is outstanding, the meals our...

INmune Bio, Inc. Announces Lead Drug Candidate XPro1595 Receives Chemical Drug Name pegipanermin from...

TW's Take: The key quote from this PR, "We look forward to advancing this novel compound into Phase 2 studies in two CNS indications...

Resetting Expectations for TFF Pharma

Thin Film Freezing, the drug delivery method being developed by TFF Pharma (TFFP), is an exciting technology that has the potential to change the...

Reversal of Fortune

The pendulum had swung too far. Simply put, companies that are funded and executing on their gameplan cannot go down forever. Eventually they find...

Gas Lines and Inflation…Is This The 80’s?

This past week saw yet another ugly market for micro-caps as the whole investment community seems to be increasingly worried about inflation and interest...

INmune Bio, Inc. Announces First Quarter 2021 Results and Provides Business Update

TW's Take: INmune continues to make solid progress on all fronts. The rest of 2021 should have some exciting catalysts with Quellor data, Xpro...

Alpha-Bet Soup

There are times when stock picking isn't the most important part of your investment strategy. When all that matters is being in the right...

The Lows Appear To Be In Place

Earlier this year I was preaching caution. The markets were en fuego and, simply put, this cannot last. While I run pretty fully invested...

XPro1595: A Next-Generation TNF Inhibitor

We had the opportunity to meet virtually with INmune Bio (INMB) recently. In that meeting, with their CFO, David Moss, and Director of Neuroscience,...

How Long Can You Hold A Soccer Ball Under Water?

Last week I wrote about INmune Bio (INMB). In that piece, In Defense of INmune, I discussed the increasing spread between perception of what's...

In Defense of INmune

I invest in "public venture capital" stocks. The typical company around here is early stage, has no revenue and is burning cash on a...

A Catalyst Filled Quarter Lies Around The Corner

My wife and I spent Good Friday in the car, driving up to Massachusetts to visit my number one newsletter fan; my mother. It...

2nd Degree of Risk

Investing in micro-caps always involves a high degree of risk. This risk can come in many different forms as well. For example, looking at...

Blood In The Water

Good Morning Vietnam! Okay, I'll confess to exaggerating a little; I neither live nor work in a war zone. It only just felt like...

Riding the Waves

This is without a doubt the most amazing market of my career. It's obviously a bull market as indexes continue to head higher. But,...

Trading Blog: INmune (INMB) and Cassava (SAVA)

~ Trade alerts discuss changes to Tailwinds' managed portfolios. They are available for premium subscribers only. The information contained here is not meant to...

The GameStop Impact…January In Review

What a crazy way to end a wild month, huh? As GameStop (GME) continued to rally in the face of shorts, Robin Hood required...

When Will The Music Stop?

When you write a newsletter, being speechless is not a great place to be. However, what I'm seeing in the market right now leaves...

INmune…Meaningful Progress in Alzheimer’s Disease

This morning INmune (INMB) presented data from their phase 1b trial in Alzheimer's Disease and hosted a KOL call to discuss the data. Although...

INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients...

TW's Take: amazing data. INmune is on a path to be part of the solution for Alzheimer's Disease, a massive market. This is incredibly...

Next Up? INmune’s Big Week Finally Arrives

Frequently I hear from investors that something sounds, "too good to be true." And, being honest, more often than not, that's the case. But,...

LLY’s $20 Billion Bonanza Bodes Well For INMB

This week Eli Lilly (LLY) reported data from their phase 2 Alzheimer's trial, TRAILBLAZER-ALZ. Based on the results of this data, shares in LLY...

INmune Bio, Inc. to Host Key Opinion Leader Webinar on Thursday, January 21 at...

TW's Take: very excited to see this data which will only reinforce and add to the smaller set of outstanding interim data the Company...

BOOM…Atomera Deal Highlights Another Bull Ride In The Market

Nothing seems to be able to get in the way of this bull market. An insurrection in DC? Yawn. The next administration taking on...

Ho Ho Ho, Santa Rally Caps Bizarre Year

They say the best presents come in small packages, right? Well, Santa is delivering this year in a big way. And, the best gifts...

The Squeeze Is On

This week saw a continued rally in the market with smaller stocks continuing their outperformance. It has been an impressive run and looks likely,...

The Micro-Cap Rally Continues Full Force

November was truly a month to remember for the markets. The best month in over 40 years for the Russell 2000 saw that index...

Timing Is Everything…Or Is It?

The market's rally, especially in small-cap, continued this past week and Tailwinds' stocks participated along with the broader indexes. In particular, performance of our...

Pfizer Develops a Vaccine…Implications for Tailwinds

On Monday morning, Pfizer (PFE) announced that they have a very effective vaccine for Covid-19. This, combined with what appears to be a clear...

INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for...

Tailwinds' Take: very positive news for a stock that has been awaiting some. We believe that Quellor will be very effective in reducing cytokine...

Moving Week

What do Donald Trump and I have in common? We are both in the process of moving... This week we found out that Joe Biden...

TFFP, INMB, OTRK…Earnings Logjam At Tailwinds

Yesterday afternoon, to my sheer delight, three companies in which I and/or my readers have large holdings all reported earnings at the same time....

INmune Bio, Inc. Announces Third Quarter Results and Provides Business Update

LA JOLLA, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness...

Sell Mortimer, Sell!!!

What do I want to say? That's the question that comes into my head every Saturday morning. This newsletter is an opportunity. An opportunity...

Post Traumatic Investment Disease Redux? Nah, Just A Dose Of Reality

Having survived the rocky cliffs of Moab, I think I jinxed myself with last week's cover photo asking "What could go wrong?" Turns out...

The Final Push…

Like the debate, 2020 has been a sh**-show. Pandemics, political divisiveness, fires...it's not been a beach party to say the least. Yet, here we stand...

West Bound and Down

After fortuitously sheltering in place on the east coast for seven weeks, we are heading back for CA this week. We seem to have,...

INmune Bio, Inc. Awarded $2.9 Million NIH Small Business Innovation Research Grant to Support...

Tailwinds' Take: to quote CEO, RJ Tesi, "This award reinforces one of INmune Bio’s fundamental drug development tenets – by targeting the underlying biology,...

Under The Radar…Key Data-Points From The Last Week That Nobody Really Noticed

The easiest way to make money in the market is trading off of insider information. It is also highly illegal, will put you in...

Hello Fall!

What a difference a week makes. Last Saturday I was writing about an epic (for Tailwinds) stretch of performance and salivating over all the...

INmune Bio, Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office Covering...

Tailwinds' Take: good news as INmune's INKmune program, which has shown great early stage data, is now protected. INMB continues to execute on two...

INmune Bio, Inc. Announces FDA Acceptance of IND Application to Evaluate Quellor™ in a...

Tailwinds' Take: great news as we believe Quellor has a great opportunity to not only have a positive impact in Covid-19 but also the...

Goodbye August (almost)…

Okay, I know it's not the official end of August...that takes place on Monday. However, due to the fact that the month is basically...

This Week at Tailwinds

Stocks continued to climb the proverbial wall of worry last week, with the S&P briefly managing to touch an all-time high and the Russell...

European Patent Granted Covering INmune Bio’s XPro1595

Tailwinds' Take: important to obtain a patent for the very large European market. XPro1595 has blockbuster potential for INMB. Very excited to see more...

OnTrak For A Great Year

Telehealth was the all the rage this past week. First The Centers for Medicare & Medicaid Services (CMS) is proposing changes to expand telehealth...

INmune Earnings Conference Call Transcript

David J. Moss Thank you Malika, and good afternoon everybody. We thank you for joining us for the call for INmune Bio’s second quarter 2020...

INmune Bio, Inc to Present at the BTIG Virtual Biotechnology Conference 2020

Tailwinds' Take: BTIG banked their recent financing and now is hosting them at a conference. Could research be coming soon? LA JOLLA, Calif, Aug. 03,...

July Recap, August Preview…Best Month Yet at Tailwinds

Here I am on my first plane flight since Covid became a word used in our everyday vernacular. Things seem pretty much the same...

INmune Bio, Inc. Prices Public Offering of Common Stock

Tailwinds' Take: we view this very favorably as the only "negative" in the INMB story was their lack of capital. They are now funded...

INMB’s XPro1595…A Potential Disease Modifying Therapy for Alzheimer’s

"When they reached the end of their 12 week trial, this family was willing to do anything to remain on the drug...because it had...

INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in...

Tailwinds' Take: this is very positive data. The reduction in white matter is particularly encouraging as there is direct correlation between this reduction and...

INmune Bio, Inc. to Announce Interim Data from Phase Ib Clinical Study of XPro1595...

Tailwinds' Take: with the trial being open-label, INmune has been able to see the data all along. Therefore, one can assume that they are...

Happy 4th of July…A Review of June and Other Notes

With June closing out, we can now reflect on what was the best quarter the stock market has seen since the turn of the...

Summer is Coming

When you receive this newsletter, it will be June 21st, the official start of summer. Typically for stocks you have a summer doldrums, "sell...

INmune Bio, Inc. Receives Regulatory Approval from UK MHRA to Initiate Phase I Trial...

Tailwinds' Take: first-in-man for their second product line is a major accomplishment for the Company. By targeting the innate immune system's NK cells, INKmune...

Killers at the Crossroad – A Published Review of Innate Immune Cell Potential in...

Tailwinds' Take: the scientific publication linked here is a great summation of the potential of NK cells in fighting cancer. INMB's INKmune program has...

Bada Bing Bada Boom

As if on cue, the market took a turn lower last week. This will be but a quick note on the market, as I'm...

INmune Bio, Inc. Announces First Quarter 2020 Results and Provides Business Update

Tailwinds' Take: submitting an IND for Covid-19 this month is the biggest potential near term driver, but there are lots of shots on goal...

INmune Bio Inc’s INB03 Inhibits Cell Migration, Tumor Growth, and Induces Innate Immune Response...

Tailwinds' Take: further evidence of the broad-scale applications possible by reducing soluble TNF and associated inflammation. INB03 has the potential to be used in...

The Week In Review

The market continues to ignore my bearish calls and, instead, keeps chugging higher. I'm at a loss to explain this, as are most professional...

The Eye Of The Storm…This Week In Tailwinds’ World

Well, I've been expecting it and it appears that it's here. The market put up one of its best months ever in April, but...

Anixa and INmune: Unique COVID-19 Opportunities In Tailwinds’ Universe

CoronaVirus is not only the buzzword for the whole market both on the negative side as business falls off a cliff, and positively as...

This Week in Stocks

While the markets may not have had the most volatile week of the year, nor come close, it was a very topsy-turvy five days...

Frontiers in Oncology Publishes an Invited Review Highlighting Soluble TNF’s Impact on Breast Cancer

Tailwinds' Take: more evidence on the negative role that soluble TNF plays in many diseases. INMB's ability to neutralize soluble TNF without associated immuno-supression...

INmune Bio Announces Allowance of U.S. Patent Covering Method for Treating Cancer by In...

Tailwinds' Take: patents show the uniqueness of INKmune, which is set to start two clinical trials this year. INMB is one of the most...

INmune Bio (INMD) Conference Call on COVID19 Program Transcript

INmune Bio DN-TNF Clinical Trial, Complications of Cytokine Storm Caused by COVID-19 April 20, 2020 Presenter R.J. Tesi, CEO and Chief Medical Officer David Moss, CFO Q&A Participants John Aschoff -...

INmune Addresses COVID-19

Monday morning, INmune Bio (INMB) announced that they were pursuing a clinical program to determine if the Company’s TNF Inhibitor (DN-TNF) platform could help...

INmune Bio, Inc. Announces Initiation of Clinical Program Targeting Soluble TNF to Determine if...

Tailwinds' Take: this Phase II trial is going to happen quickly. Inflammation is a big part of the problems associated with CV19 and INmune's...

Saturday Morning Ramblings…

Another great week in the market. The economy is in free-fall, unemployment is skyrocketing and stocks can't stop going up. How is this possible?...

IF Alpha?

My biggest concern last fall was, "what if Bernie gets into office?" This fear was driven partially by the fact that the market would...

INMB: INmune Bio Earnings Call Transcript

INmune Bio, Inc. Fourth Quarter and Full Year 2019 Earnings Call March 11, 2020, 11 AM  Presenters Landon Baretto, Moderator Raymond J. Tesi, MD, CEO David J....
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.